Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Linde PLC (LIN) vs Philip Morris International Inc. (PM) Price & Performance

Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

Linde PLC vs Philip Morris International Inc. — how do they compare? Linde PLC trades at $483.98 (market cap $222.05B), while Philip Morris International Inc. trades at $201 (market cap $312.50B). The key difference: Philip Morris International Inc. is the larger of the two by market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Philip Morris International Inc. for 85 Days on average.

LINPM
Market Cap
$222.05B$312.50B
Volume
2,116,4405,517,172
Sector
Basic MaterialsConsumer Staples
52-Week High
$546.64$200.50
52-Week Low
$389.38$144.33
Typical Hold Time
88 Days85 Days
Enterprise Value
$245.17B$355.62B
Dividend Yield
1.33%3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Linde PLC

LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.

The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.

Philip Morris International Inc.

Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.

Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LIN
0% Buy100% Sell
Avg holding period · 88 Days
PM
1% Buy99% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →